Cargando…

Generation, characterization, and drug sensitivities of 12 patient-derived IDH1-mutant glioma cell cultures

BACKGROUND: Mutations of the isocitrate dehydrogenase (IDH) gene occur in over 80% of low-grade gliomas and secondary glioblastomas. Despite considerable efforts, endogenous in vitro IDH-mutated glioma models remain scarce. Availability of these models is key for the development of new therapeutic i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Verheul, Cassandra, Ntafoulis, Ioannis, Kers, Trisha V, Hoogstrate, Youri, Mastroberardino, Pier G, Barnhoorn, Sander, Payán-Gómez, César, Tching Chi Yen, Romain, Struys, Eduard A, Koolen, Stijn L W, Dirven, Clemens M F, Leenstra, Sieger, French, Pim J, Lamfers, Martine L M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Basic and Translational Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478778/ https://www.ncbi.nlm.nih.gov/pubmed/34595478 http://dx.doi.org/10.1093/noajnl/vdab103

Ejemplares similares

Drug Repurposing, a Fast-Track Approach to Develop Effective Treatments for Glioblastoma
por: Ntafoulis, Ioannis, et al.
Publicado: (2022)

Effects of the IDH1 R132H Mutation on the Energy Metabolism: A Comparison between Tissue and Corresponding Primary Glioma Cell Cultures
por: Dekker, Lennard J. M., et al.
Publicado: (2022)

Advancements, Challenges, and Future Directions in Tackling Glioblastoma Resistance to Small Kinase Inhibitors
por: Fabro, Federica, et al.
Publicado: (2022)

The In Vivo Therapeutic Efficacy of the Oncolytic Adenovirus Delta24-RGD Is Mediated by Tumor-Specific Immunity
por: Kleijn, Anne, et al.
Publicado: (2014)

Genomic Exploration of Distinct Molecular Phenotypes Steering Temozolomide Resistance Development in Patient-Derived Glioblastoma Cells
por: Fabro, Federica, et al.
Publicado: (2023)

ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells
por: Balvers, Rutger K, et al.
Publicado: (2015)

Longitudinal characteristics of T2-FLAIR mismatch in IDH-mutant astrocytomas: Relation to grade, histopathology, and overall survival in the GLASS-NL cohort
por: van Garderen, Karin A, et al.
Publicado: (2023)

IDH1-mutated transgenic zebrafish lines: An in-vivo model for drug screening and functional analysis
por: Gao, Ya, et al.
Publicado: (2018)

Comparative single-cell RNA-sequencing profiling of BMP4-treated primary glioma cultures reveals therapeutic markers
por: Verploegh, Iris S C, et al.
Publicado: (2022)

Landscape of driver gene events, biomarkers, and druggable targets identified by whole-genome sequencing of glioblastomas
por: van de Geer, Wesley S, et al.
Publicado: (2021)

Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers
por: Ntafoulis, Ioannis, et al.
Publicado: (2023)

Novel kinome profiling technology reveals drug treatment is patient and 2D/3D model dependent in glioblastoma
por: Fabro, Federica, et al.
Publicado: (2022)

Locally-Delivered T-Cell-Derived Cellular Vehicles Efficiently Track and Deliver Adenovirus Delta24-RGD to Infiltrating Glioma
por: Balvers, Rutger K., et al.
Publicado: (2014)

The HDAC Inhibitors Scriptaid and LBH589 Combined with the Oncolytic Virus Delta24-RGD Exert Enhanced Anti-Tumor Efficacy in Patient-Derived Glioblastoma Cells
por: Berghauser Pont, Lotte M.E., et al.
Publicado: (2015)

The Bcl-2 inhibitor Obatoclax overcomes resistance to histone deacetylase inhibitors SAHA and LBH589 as radiosensitizers in patient-derived glioblastoma stem-like cells
por: Berghauser Pont, Lotte M.E., et al.
Publicado: (2014)

The EGFRvIII transcriptome in glioblastoma: A meta-omics analysis
por: Hoogstrate, Youri, et al.
Publicado: (2021)

The Sequence of Delta24-RGD and TMZ Administration in Malignant Glioma Affects the Role of CD8(+)T Cell Anti-tumor Activity
por: Kleijn, Anne, et al.
Publicado: (2017)

EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligand
por: Hoogstrate, Youri, et al.
Publicado: (2019)

Multiomics profiling of paired primary and recurrent glioblastoma patient tissues
por: Dekker, Lennard J M, et al.
Publicado: (2020)

Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy
por: Belcaid, Zineb, et al.
Publicado: (2020)

Personalizing Oncolytic Virotherapy for Glioblastoma: In Search of Biomarkers for Response
por: Stavrakaki, Eftychia, et al.
Publicado: (2021)

Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma
por: Kessler, Tobias, et al.
Publicado: (2020)

Patient-derived cells from recurrent tumors that model the evolution of IDH-mutant glioma
por: Jones, Lindsey E, et al.
Publicado: (2020)

A Systematic Comparison Identifies an ATP-Based Viability Assay as Most Suitable Read-Out for Drug Screening in Glioma Stem-Like Cells
por: Kleijn, A., et al.
Publicado: (2016)

IDH mutation status is associated with distinct vascular gene expression signatures in lower-grade gliomas
por: Zhang, Lei, et al.
Publicado: (2018)

Cystathionine-γ-lyase drives antioxidant defense in cysteine-restricted IDH1-mutant astrocytomas
por: Cano-Galiano, Andrés, et al.
Publicado: (2021)

Tumor mutational burden predicts survival in patients with low-grade gliomas expressing mutated IDH1
por: Alghamri, Mahmoud S, et al.
Publicado: (2020)

Identification of subsets of IDH-mutant glioblastomas with distinct epigenetic and copy number alterations and stratified clinical risks
por: Li, Kay Ka-Wai, et al.
Publicado: (2019)

Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations
por: Tesileanu, C. Mircea S., et al.
Publicado: (2021)

Prognostic impact of PDGFRA gain/amplification and MGMT promoter methylation status in patients with IDH wild-type glioblastoma
por: Higa, Nayuta, et al.
Publicado: (2022)

Prediction of transient tumor enlargement using MRI tumor texture after radiosurgery on vestibular schwannoma
por: Langenhuizen, Patrick P. J. H., et al.
Publicado: (2020)

Monitoring response to a clinically relevant IDH inhibitor in glioma—Hyperpolarized (13)C magnetic resonance spectroscopy approaches
por: Hong, Donghyun, et al.
Publicado: (2023)

Does early resection of presumed low-grade glioma improve survival? A clinical perspective
por: Wijnenga, Maarten M. J., et al.
Publicado: (2017)

Gamma knife radiosurgery for recurrent gliomas
por: Sadik, Zjiwar H. A., et al.
Publicado: (2018)

Glycolytic expression in lower-grade glioma reveals an epigenetic association between IDH mutation status and PDL1/2 expression
por: Givechian, Kevin B, et al.
Publicado: (2020)

Recent advances in the molecular understanding of glioblastoma
por: Bleeker, Fonnet E., et al.
Publicado: (2012)

Prognostic relevance of mutations and copy number alterations assessed with targeted next generation sequencing in IDH mutant grade II glioma
por: Wijnenga, Maarten M. J., et al.
Publicado: (2018)

Blood-based extracellular matrix biomarkers are correlated with clinical outcome after PD-1 inhibition in patients with metastatic melanoma
por: Hurkmans, Daan P, et al.
Publicado: (2020)

TP53, ATRX alterations, and low tumor mutation load feature IDH-wildtype giant cell glioblastoma despite exceptional ultra-mutated tumors
por: Cantero, Diana, et al.
Publicado: (2020)

Improved risk stratification in younger IDH wild-type glioblastoma patients by combining a 4-miRNA signature with MGMT promoter methylation status
por: Unger, Kristian, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_m0f1h9ueih0c636ia3frbce342